Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|5|417-421

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.5, 2015-05, pp. : 417-421

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 120-124

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ofatumumab for the treatment of chronic lymphocytic leukemia

By Robak Tadeusz  

Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. : 577-587

Future Medicine

Access to resources Recommend Favorite

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 40-49

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 1, 2015-01 ,pp. : 37-42

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II trial of ofatumumab plus ESHAP (O‐ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first‐line chemotherapy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 174, Iss. 6, 2016-09 ,pp. : 859-867

John Wiley & Sons Inc

Access to resources Recommend Favorite